Dr Reddy's Q4 profit jumps 76% to Rs 764 cr on higher sales in US, Europe; revenue up 10% at Rs 4,432 cr

Dr Reddy's said various initiatives have been undertaken to ensure that our manufacturing-related operations continue unabated enabling it to serve the patients.

Asian News International May 20, 2020 16:35:08 IST
Dr Reddy's Q4 profit jumps 76% to Rs 764 cr on higher sales in US, Europe; revenue up 10% at Rs 4,432 cr

Hyderabad: Dr Reddy's Laboratories Ltd on Wednesday reported a net profit of Rs 764 crore during the January to March quarter, up 76 percent from Rs 434 crore in the corresponding quarter of the previous financial year.

The company reported a revenue of Rs 4,432 crore, up 10 percent from the year-ago period. Its global generics segment clocked 20 percent year-on-year jump to Rs 3,640 crore.

The earnings before interest, taxes, depreciation and amortisation (EBITDA) came at Rs 1,001 crore while EBITDA margin was at 22.6 percent.

Dr Reddys Q4 profit jumps 76 to Rs 764 cr on higher sales in US Europe revenue up 10 at Rs 4432 cr

Representational image. News18

"FY 20 has been a very positive year for the company," said co-Chairman and Managing Director GV Prasad.

"Progress made during the year includes VAi status for CTO 6, healthy product pipeline build-up, productivity improvement and strong financial performance across our businesses."

Among the geographies, Europe's segment saw a jump of 80 percent in revenue while North America and emerging markets rose 21 percent and 15 percent respectively.

India segment rose 5 percent year-on-year.

Dr Reddy's said various initiatives have been undertaken to ensure that its manufacturing-related operations continue unabated enabling it to serve the patients.

A few products related to COVID-19 are under development.

The board of directors has recommended a final dividend of Rs 25 (500 percent) per equity share of Rs 5 face value for the financial year 2019-20.

During the quarter, Dr Reddy's acquired select divisions of Wockhardt Ltd's branded generics business in India and a few other international territories like Nepal, Sri Lanka, Bhutan and Maldives.

The deal comprising a portfolio of 62 brands in multiple therapy areas was done on a slump sale basis for a consideration of Rs 1,850 crore.

Updated Date:

also read

Vaccinated people could get COVID-19 but it's unclear whether they can spread the virus, scientists say
science

Vaccinated people could get COVID-19 but it's unclear whether they can spread the virus, scientists say

Recent data suggests that it’s much harder for vaccinated people to get infected, but it's not impossible.

India records 1,61,736 new COVID-19 cases, 879 deaths in 24 hours; fatality rate at 1.25%
India

India records 1,61,736 new COVID-19 cases, 879 deaths in 24 hours; fatality rate at 1.25%

While infections increased for the 34th day in a row, the national COVID-19 recovery rate dropped to 89.51 percent

New Zealand suspends travel from India between 11 and 28 April after surge in COVID-infected travellers
World

New Zealand suspends travel from India between 11 and 28 April after surge in COVID-infected travellers

The restriction comes after New Zealand recorded 23 new cases in managed isolation on Thursday, of which 17 came from India